CY1116075T1 - Νεες συνθεσεις λιποσωματων - Google Patents

Νεες συνθεσεις λιποσωματων

Info

Publication number
CY1116075T1
CY1116075T1 CY20151100123T CY151100123T CY1116075T1 CY 1116075 T1 CY1116075 T1 CY 1116075T1 CY 20151100123 T CY20151100123 T CY 20151100123T CY 151100123 T CY151100123 T CY 151100123T CY 1116075 T1 CY1116075 T1 CY 1116075T1
Authority
CY
Cyprus
Prior art keywords
liposome compositions
new liposome
containing compositions
lipid
targeted liposomes
Prior art date
Application number
CY20151100123T
Other languages
English (en)
Inventor
Kazushi Okada
Tadayuki Ibuki
Donghyun Kim
Tadashi Fujisawa
Original Assignee
Mebiopharm Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mebiopharm Co., Ltd. filed Critical Mebiopharm Co., Ltd.
Publication of CY1116075T1 publication Critical patent/CY1116075T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα περιγραφή παρέχει συνθέσεις που περιέχουν λιπίδια, συμπεριλαμβανομένων στοχευόμενων λιποσωμάτων που ενκαψουλιώνουν φάρμακο, και φαρμακευτικών σκευασμάτων αυτών, όπως επίσης και μεθόδους για την παρασκευή και χρήση των συνθέσεων που περιέχουν λιπίδια, συμπεριλαμβανομένης της χρήσης των στοχευόμενων λιποσωμάτων για τη θεραπεία του καρκίνου κι άλλων ασθενειών.
CY20151100123T 2005-03-10 2015-02-06 Νεες συνθεσεις λιποσωματων CY1116075T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005067469A JP2006248978A (ja) 2005-03-10 2005-03-10 新規なリポソーム製剤
EP06737793.7A EP1863448B1 (en) 2005-03-10 2006-03-08 Novel liposome compositions

Publications (1)

Publication Number Publication Date
CY1116075T1 true CY1116075T1 (el) 2017-02-08

Family

ID=36992280

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100123T CY1116075T1 (el) 2005-03-10 2015-02-06 Νεες συνθεσεις λιποσωματων

Country Status (22)

Country Link
US (3) US7829113B2 (el)
EP (1) EP1863448B1 (el)
JP (2) JP2006248978A (el)
KR (1) KR101352490B1 (el)
CN (1) CN101170995B (el)
AU (1) AU2006223329B2 (el)
BR (1) BRPI0608297A2 (el)
CA (1) CA2600446A1 (el)
CY (1) CY1116075T1 (el)
DK (1) DK1863448T3 (el)
ES (1) ES2529453T3 (el)
HK (1) HK1111625A1 (el)
HU (1) HUE024290T2 (el)
MX (1) MX2007010996A (el)
NO (1) NO20075136L (el)
NZ (1) NZ561569A (el)
PL (1) PL1863448T3 (el)
PT (1) PT1863448E (el)
RU (1) RU2454229C2 (el)
SI (1) SI1863448T1 (el)
WO (1) WO2006099169A2 (el)
ZA (1) ZA200708600B (el)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4971142B2 (ja) 2004-05-03 2012-07-11 ヘルメス バイオサイエンシズ インコーポレーティッド 薬物送達に有用なリポソーム
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
WO2009097011A1 (en) * 2007-08-17 2009-08-06 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
DK2200431T3 (en) 2007-09-10 2016-08-15 Boston Biomedical Inc UNKNOWN COMPOSITIONS AND PROCEDURES FOR CANCER TREATMENT
TWI468188B (zh) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
EP2451950B9 (en) * 2009-07-06 2016-11-23 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
US8956600B2 (en) 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US8591942B2 (en) 2009-09-23 2013-11-26 Indu JAVERI Methods for the preparation of liposomes comprising docetaxel
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
US9730909B2 (en) 2010-03-19 2017-08-15 Boston Biomedical, Inc Methods for targeting cancer stem cells
WO2011128896A1 (en) * 2010-04-12 2011-10-20 Ramot At Tel-Aviv University Ltd. Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders
CA2817755C (en) 2010-11-12 2021-07-06 Rachael Terry Modified immune-modulating particles
WO2012153616A1 (ja) * 2011-05-10 2012-11-15 国立大学法人北海道大学 標的細胞移行能を有する脂質膜構造体、その製造方法および標的細胞において効果を示す物質のスクリーニング方法
WO2013011598A1 (ja) * 2011-07-15 2013-01-24 コニカミノルタホールディングス株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
CN104080480A (zh) * 2012-01-01 2014-10-01 奇比艾企业有限公司 用于选择性递送治疗剂和诊断剂的endo180靶向微粒
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
KR20220166879A (ko) 2012-06-21 2022-12-19 노쓰웨스턴유니버시티 펩티드 접합된 입자
ES2733061T3 (es) 2012-08-10 2019-11-27 Taiho Pharmaceutical Co Ltd Dispersión acuosa de liposomas encapsulantes de oxaliplatino estable y método para estabilización de la misma
US10188728B2 (en) 2012-12-12 2019-01-29 Temple University—Of the Commonwealth System of Higher Education Compositions and methods for treatment of cancer
CN103083239B (zh) * 2012-12-26 2015-11-25 中国人民解放军第四军医大学 一种蟾毒灵脂质体及其制备方法和应用
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
US9913883B2 (en) 2013-03-13 2018-03-13 Cour Pharmaceuticals Development Company Immune-modifying nanoparticles for the treatment of inflammatory diseases
MX2015012199A (es) * 2013-03-13 2015-11-30 Mallinckrodt Llc Composiciones de cisplatino liposomal para la terapia contra el cancer.
MX2015012200A (es) * 2013-03-13 2015-11-30 Mallinckrodt Llc Composiciones de oxaliplatino en liposomas para la terapia contra el cancer.
AU2014250940A1 (en) 2013-04-09 2015-10-22 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
SI3033102T2 (sl) 2013-08-13 2024-03-29 Northwestern University Peptid konjugirani delci
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
WO2016070129A1 (en) 2014-10-30 2016-05-06 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US20170007700A1 (en) * 2014-02-21 2017-01-12 The Curators Of The University Of Missouri Compositions and methods for boron neutron capture therapy
EP4079847A1 (en) 2014-07-30 2022-10-26 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2016208481A1 (ja) 2015-06-24 2016-12-29 日本化薬株式会社 新規白金（ｉｖ）錯体
JP7042739B2 (ja) 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
WO2017034957A1 (en) 2015-08-21 2017-03-02 Merrimack Pharmaceuticals, Inc. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
JP6725520B2 (ja) 2015-09-14 2020-07-22 日本化薬株式会社 ６配位白金錯体の高分子結合体
JP6941606B2 (ja) 2015-10-16 2021-09-29 イプセン バイオファーム リミティド 安定化カンプトテシン医薬組成物
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and their uses
US20180318216A1 (en) * 2015-11-20 2018-11-08 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
AU2016374759B2 (en) 2015-12-22 2021-04-01 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of sulfoxide derivative-coordinated platinum(II) complex
CN109678910B (zh) 2016-01-25 2021-09-07 沈阳药科大学 一种化合物及其应用以及一种铂类配合物及其脂质体
CN109312341B (zh) * 2016-03-07 2024-02-27 美国政府(由卫生和人类服务部的部长所代表) 微小rna及其使用方法
KR102194109B1 (ko) * 2016-04-15 2020-12-22 후지필름 가부시키가이샤 마이크로니들 어레이
JP7019201B2 (ja) * 2016-08-02 2022-02-15 キュリアールエックス インコーポレーテッド リポソームの調製方法
AU2017306676B2 (en) 2016-08-03 2024-02-22 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
EP3497214B1 (en) 2016-08-09 2023-06-28 President and Fellows of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
EP3496756A4 (en) 2016-08-12 2020-07-22 L.E.A.F Holdings Group LLC ALPHA- AND GAMMA-D-POLYGLUTAMATED ANTIFOLATES AND USES THEREOF
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
JP2019530464A (ja) 2016-10-14 2019-10-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基エディターのａａｖ送達
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
EP3538546A1 (en) 2016-11-14 2019-09-18 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
CA3063395A1 (en) * 2017-05-12 2018-11-15 Curinanorx, Llc Methods for the preparation of liposomes comprising drugs
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
AU2018352592A1 (en) 2017-10-16 2020-06-04 Beam Therapeutics, Inc. Uses of adenosine base editors
JP7491572B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化ペメトレキセドおよびその使用
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US11771700B2 (en) 2018-02-14 2023-10-03 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
CN108524450A (zh) * 2018-04-16 2018-09-14 温州医科大学 基于磁性热敏阳离子脂质体的奥沙利铂和mdc1-as共传递药物载体的制备及应用
JP7483193B2 (ja) 2018-06-13 2024-05-15 カリフォルニア・インスティテュート・オブ・テクノロジー 血脳バリアを越えるためのナノ粒子とそれを用いた治療法
KR20210068485A (ko) 2018-09-28 2021-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 노화를 역전시키고 기관 및 조직 재생을 촉진시키기 위한 세포 재프로그래밍
CN113166783A (zh) 2018-10-09 2021-07-23 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和***以及与之相关的方法
EP3942040A1 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CN111721841B (zh) * 2019-03-19 2022-07-12 海南长安国际制药有限公司 与洛铂有关物质的检测
CN110292563B (zh) * 2019-06-12 2021-07-16 兰州大学 基于叶酸热敏脂质体的阴离子载体诱导癌细胞凋亡的方法
JP2023521042A (ja) 2020-04-02 2023-05-23 ミレキュール インコーポレイテッド 操作されたオリゴヌクレオチドを使用する標的化された阻害
MX2022014008A (es) 2020-05-08 2023-02-09 Broad Inst Inc Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
CN112129871B (zh) * 2020-09-04 2021-06-15 斯微(上海)生物科技有限公司 复合磷脂脂质体中dope和m5两种磷脂含量的检测方法
CN112870164B (zh) * 2021-01-25 2021-12-17 山东大学 一种双靶向载药脂质体及其制备方法和应用
WO2023196851A1 (en) 2022-04-06 2023-10-12 President And Fellows Of Harvard College Reversing aging of the central nervous system

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GR75598B (el) 1980-04-29 1984-08-01 Sanofi Sa
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
US4789633A (en) 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US4925661A (en) * 1984-04-19 1990-05-15 Leaf Huang Target-specific cytotoxic liposomes
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4762915A (en) * 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
EP0211042A1 (en) * 1985-01-18 1987-02-25 Cooper-Lipotech, Inc. Liposome composition and method
US5026651A (en) * 1985-04-25 1991-06-25 Board Of Regents, The University Of Texas System Methods and compositions for the production of human transferrin
PH26160A (en) * 1985-08-19 1992-03-18 Univ Texas Pharmaceutical compositions consisting of acylated phospholipids
US4983397A (en) * 1985-08-19 1991-01-08 Board Of Regents, University Of Texas System Pharmaceutical compositions consisting of acylated phospholipids
US5384127A (en) * 1985-10-18 1995-01-24 Board Of Regents, The University Of Texas System Stable liposomal formulations of lipophilic platinum compounds
JPH0714865B2 (ja) * 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
US5049390A (en) * 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
FR2631826B1 (fr) * 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
EP1327454A3 (en) * 1989-08-02 2003-12-03 Mitra Medical Technology AB Method of treatment with medical agents
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1992005773A1 (en) * 1990-10-09 1992-04-16 Vestar, Inc. Phospholipid analogue vesicle with a succinimidyl moiety
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US6509032B1 (en) 1991-08-28 2003-01-21 Mcmaster University Cationic amphiphiles
US5292524A (en) * 1991-09-06 1994-03-08 California Institute Of Technology Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
JPH0776230B2 (ja) 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JP2673331B2 (ja) * 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
JPH06287021A (ja) 1992-04-22 1994-10-11 Tanaka Kikinzoku Kogyo Kk 光学活性な白金錯化合物の光学的分割方法
US20030190638A1 (en) 1992-05-13 2003-10-09 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
US20030100489A1 (en) * 1992-10-16 2003-05-29 Beach David H. Cell-cycle regulatory proteins, and uses related thereto
US5962316A (en) * 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
AU6833994A (en) 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
JP3025602B2 (ja) * 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
JP2852127B2 (ja) * 1993-10-06 1999-01-27 アムジエン・インコーポレーテツド 安定なタンパク質：リン脂質組成物及び方法
WO1995016774A1 (en) * 1993-12-17 1995-06-22 Spinal Cord Society Method for inducing dna synthesis in neurons
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
JP3590983B2 (ja) * 1994-03-04 2004-11-17 日本油脂株式会社 リン脂質誘導体
WO1995026205A1 (en) 1994-03-28 1995-10-05 Nycomed Imaging A/S Liposomes
ES2143058T3 (es) 1994-07-29 2000-05-01 Abbott Lab Procedimiento de preparacion de un 2,5-diamino-3-hidroxihexano sustituido.
CZ286714B6 (en) 1994-08-08 2000-06-14 Debiopharm Sa Pharmaceutically stable preparation based on oxaliplatinum
WO1996011670A1 (en) * 1994-10-14 1996-04-25 The Liposome Company, Inc. Ether lipid liposomes and their therapeutic use
DE69531722T2 (de) * 1994-11-11 2004-07-01 Debiopharm S.A. Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten
US5786214A (en) * 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
TW319763B (el) 1995-02-01 1997-11-11 Epix Medical Inc
US5780052A (en) * 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
US5834012A (en) * 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US20020022264A1 (en) 1995-05-26 2002-02-21 Sullivan Sean M. Delivery vehicles comprising stable lipid/nucleic acid complexes
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
JPH09278785A (ja) 1996-04-10 1997-10-28 Tanaka Kikinzoku Kogyo Kk 白金化合物の製造方法
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US6428977B1 (en) 1995-12-20 2002-08-06 Curis, Inc. Signalin family of TGFβ signal transduction proteins, and uses related thereto
JP3735921B2 (ja) * 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
AU2112697A (en) * 1996-02-09 1997-08-28 Pi-Wan Cheng Receptor ligand-facilitated delivery of biologically active molecules
WO1997033894A1 (fr) 1996-03-11 1997-09-18 Debiopharm Sa Complexes de platine dinucleaires, procede pour leur preparation et compositions pharmaceutiques en contenant
JP2001521486A (ja) * 1996-03-28 2001-11-06 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 改良リポソーム組成物を製造するための材料および方法
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
US6228391B1 (en) * 1996-05-02 2001-05-08 Terumo Kabushiki Kaisha Amidine derivatives and drug carriers comprising the same
CA2263455C (en) 1996-08-23 2002-10-29 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
NZ514133A (en) 1996-10-15 2001-09-28 Liposome Co Inc N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
DK0964690T3 (da) * 1996-10-15 2003-10-20 Liposome Co Inc Peptid-lipidkonjugater, liposomer og liposomal lægemiddeladministration
AU5729898A (en) 1996-12-18 1998-07-15 Emory University Polycationic oligomers
JP2001513110A (ja) 1997-03-07 2001-08-28 サノフィ−シンテラボ インコーポレイティド 腫瘍治療方法
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
JPH10253632A (ja) * 1997-03-10 1998-09-25 Nissui Pharm Co Ltd 分析方法、キット及び装置
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6524613B1 (en) * 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
US6272370B1 (en) * 1998-08-07 2001-08-07 The Regents Of University Of Minnesota MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging
WO1998059035A2 (en) 1997-06-25 1998-12-30 The Goverment Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health Serum-free cell growth medium
US6165719A (en) * 1997-07-15 2000-12-26 The Regents Of The University Of California hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target
DE69838584T2 (de) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
KR20010030854A (ko) * 1997-10-02 2001-04-16 로퍼, 랜달 비. 인터벤셔날 요법을 모니터하기 위한 콘트라스트 강화된진단 영상화 방법
US6749863B1 (en) * 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US6320017B1 (en) * 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
US6573101B1 (en) * 1998-02-12 2003-06-03 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6245427B1 (en) * 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
PT1121117E (pt) * 1998-10-14 2002-10-31 Debiopharm Sa Acondicionamento de uma preparacao de oxaliplatina
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US7312318B2 (en) * 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
CA2369397A1 (en) 1999-05-17 2000-11-23 Avi Biopharma, Inc. Combined approach to treatment of cancer with hcg vaccines
JP2001002592A (ja) 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd 遺伝子導入用組成物
US6280054B1 (en) * 1999-07-02 2001-08-28 Zight Corporation Image generator having an improved illumination system
US6242188B1 (en) 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
WO2001011826A1 (fr) * 1999-08-09 2001-02-15 Fujitsu Limited Dispositif et technique de commande de paquets
ATE249825T1 (de) 1999-08-30 2003-10-15 Debiopharm Sa Oxaliplatinhaltige parenteral anzuwendende stabilisierte arzneizubereitung und verfahren zu deren herstellung
CA2395636A1 (en) 1999-12-30 2001-07-12 Novartis Ag Novel colloid synthetic vectors for gene therapy
BR0016864A (pt) 1999-12-30 2002-09-24 Judith K Gwathmey Sistema de fornecimento de quelante de ferro, e, métodos de preparação de um sistema de fornecimento de quelante de ferro e de tratamento de sobrecarga de ferro em um mamìfero em necessidade de tratamento
US7034006B2 (en) * 2000-01-10 2006-04-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US6530944B2 (en) * 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7001735B2 (en) * 2000-03-01 2006-02-21 Albert Einstein College Of Medicine Of Yeshiva University Glucose transporter/sensor protein and uses thereof
EP1262490B1 (en) * 2000-03-02 2007-10-03 Mitsubishi Pharma Corporation GPib-LIPID BOND CONSTRUCT AND USE THEREOF
JP4449147B2 (ja) 2000-03-22 2010-04-14 日油株式会社 ホスファチジルエタノールアミン誘導体の製造方法
FR2806727A1 (fr) 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
PT1272161E (pt) * 2000-04-12 2008-02-08 Liplasome Pharma As Sistemas de distribuição de fármacos à base de lípidos que contêm derivados lipídicos degradáveis da fosfolipase a2 para utilização clínica contra infecções parasitárias
AU6627201A (en) * 2000-05-03 2001-11-12 Mbt Munich Biotechnology Gmbh Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US20030059461A1 (en) * 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
US20030072794A1 (en) * 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
JP2004508385A (ja) * 2000-09-11 2004-03-18 インスティチュート・パスツール Ｖｐｒの模倣物であるＨＩＶ−１ＶＰＲによるミトコンドリア膜透過化の機構、およびＶＰＲとＡＮＴとの相互作用を変化させ、および／または妨げ、および／または模倣する能力を有する活性な分子のスクリーニング方法
US20040234588A1 (en) 2000-09-21 2004-11-25 University Of Georgia Research Foundation, Inc. Artificial lipoprotein carrier system for bioactive materials
DE60108405D1 (de) * 2000-10-03 2005-02-17 Debiopharm Sa Plga/pla-typ mikrokugeln enthaltend eine wasserlösliche verbindung und herstellungsverfahren dafür
US20030129223A1 (en) * 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
EP1209469A1 (en) 2000-11-22 2002-05-29 Vectron Therapeutics AG Production and use of a targeted diagnostic system
WO2002048671A1 (en) * 2000-12-12 2002-06-20 Australian Institute Of Marine Science Assay for paralytic shellfish toxin
AU2002223013A1 (en) 2000-12-12 2002-06-24 Debiopharm S.A. Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same
US6897196B1 (en) * 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US6703524B2 (en) * 2001-02-20 2004-03-09 Lkt Laboratories, Inc. Organoselenium compounds for cancer chemoprevention
ATE365037T1 (de) 2001-03-02 2007-07-15 Debiopharm Sa Verwendung eines eine oxaliplatinlösung beinhaltenden fläschchens
FI113840B (fi) 2001-03-26 2004-06-30 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa
US20040049022A1 (en) * 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
WO2002088318A2 (en) 2001-04-30 2002-11-07 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
US20030082228A1 (en) * 2001-05-09 2003-05-01 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
US20030108986A1 (en) * 2001-06-21 2003-06-12 Euroscreen, S.A. Compositions and methods comprising G-protein coupled receptors
US20040186172A1 (en) 2001-07-02 2004-09-23 Houssam Ibrahim Oxaliplatin active substance with a very low content of oxalic acid
US20030096299A1 (en) * 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof
WO2003015521A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
AU2002330139A1 (en) * 2001-10-03 2003-04-14 Vanderbilt University In vivo panning for ligands to radiation-induced molecules
WO2003044214A2 (en) 2001-11-20 2003-05-30 Baylor College Of Medicine Methods and compositions in checkpoint signaling
JP4468617B2 (ja) 2001-12-04 2010-05-26 デビオファーム エス．アー． 抗癌剤の併用投与方法及び併用可能な抗癌剤
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
DK1463759T3 (da) 2002-01-07 2013-08-12 Euroscreen Sa Ligand for den G-proteinkoblede receptor GPR43 og anvendelser deraf
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
WO2004065621A1 (en) * 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
WO2003082907A1 (en) 2002-03-29 2003-10-09 Euroscreen Sa Ligands for g protein coupled receptor gpr7 and uses thereof
CA2391438A1 (en) * 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
US20030228285A1 (en) 2002-05-03 2003-12-11 Mien-Chie Hung Bipartite T-cell factor (Tcf)-responsive promoter
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
JP3415131B1 (ja) 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
FR2840236B1 (fr) 2002-06-03 2005-02-04 Inst Francais Du Petrole Membrane zeolithique de faible epaisseur, sa preparation et son utilisation en separation
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
EP1511518A2 (en) * 2002-06-07 2005-03-09 Immunomedics, Inc. Neutrophil imaging methods in cystic fibrosis
MXPA04012656A (es) * 2002-06-14 2005-08-15 Immunomedics Inc Anticuerpo hpam4 monoclonal humanizado.
CA2489469C (en) * 2002-06-14 2016-03-22 Immunomedics, Inc. Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
US6790632B2 (en) 2002-06-17 2004-09-14 Stephen Eliot Zweig Membrane receptor reagent and assay
JP4722481B2 (ja) * 2002-06-28 2011-07-13 プロティバ バイオセラピューティクス リミテッド リポソーム製造方法および装置
US7300655B2 (en) 2002-08-01 2007-11-27 Immunomedics, Inc. Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof
US20040132652A1 (en) * 2002-08-30 2004-07-08 Shire Biochem Inc. Pharmaceutical compositions
WO2004045519A2 (en) 2002-11-14 2004-06-03 Kirk Sperber Induction of apoptosis by hiv-1 infected monocytic cells
AU2003280761B2 (en) 2002-11-15 2009-10-01 Nipro Corporation Liposome
AU2003277641B2 (en) 2003-02-17 2009-09-17 Mebiopharm Co., Ltd. Remedy for cancer
EP1618181B1 (en) * 2003-04-22 2014-10-15 IBC Pharmaceuticals Polyvalent protein complex
AU2004268932B2 (en) * 2003-06-13 2010-06-24 Immunomedics, Inc. D-amino acid peptides
JP4733635B2 (ja) * 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
JP2005154282A (ja) 2003-11-20 2005-06-16 Mebiopharm Co Ltd ガス封入リポソームの製造法
US7582430B2 (en) * 2004-01-20 2009-09-01 United States Of America As Represented By The Secretary Of The Army Immunoliposome-nucleic acid amplification (ILNAA) assay
US7212869B2 (en) * 2004-02-04 2007-05-01 Medtronic, Inc. Lead retention means
CN1679957B (zh) 2004-03-15 2010-06-09 尼普洛株式会社 含脂质体的癌症治疗用药物组合物
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2008030818A2 (en) 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
JP5345792B2 (ja) 2008-02-19 2013-11-20 テイ・エス テック株式会社 車両用格納シート
JP5331648B2 (ja) 2009-10-22 2013-10-30 株式会社日立製作所 微粉炭ボイラの改造方法

Also Published As

Publication number Publication date
ZA200708600B (en) 2009-01-28
US7829113B2 (en) 2010-11-09
SI1863448T1 (sl) 2015-03-31
NO20075136L (no) 2007-12-07
US8758810B2 (en) 2014-06-24
EP1863448A2 (en) 2007-12-12
PL1863448T3 (pl) 2015-05-29
KR101352490B1 (ko) 2014-02-04
WO2006099169A2 (en) 2006-09-21
AU2006223329B2 (en) 2011-11-17
HUE024290T2 (en) 2016-01-28
JP2008538105A (ja) 2008-10-09
AU2006223329A1 (en) 2006-09-21
JP5438317B2 (ja) 2014-03-12
RU2007137492A (ru) 2009-04-20
ES2529453T3 (es) 2015-02-20
NZ561569A (en) 2011-03-31
CN101170995B (zh) 2013-01-16
EP1863448B1 (en) 2014-11-26
US20110081404A1 (en) 2011-04-07
HK1111625A1 (en) 2008-08-15
US20060222696A1 (en) 2006-10-05
MX2007010996A (es) 2007-11-07
KR20080002819A (ko) 2008-01-04
RU2454229C2 (ru) 2012-06-27
DK1863448T3 (en) 2015-02-16
CN101170995A (zh) 2008-04-30
CA2600446A1 (en) 2006-09-21
PT1863448E (pt) 2015-02-10
BRPI0608297A2 (pt) 2009-12-08
US20140363491A1 (en) 2014-12-11
JP2006248978A (ja) 2006-09-21
WO2006099169A3 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
CY1116075T1 (el) Νεες συνθεσεις λιποσωματων
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
CY1121858T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτες και μεθοδοι χρησης αυτων
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
CY1119209T1 (el) Αναστολεις κινασης τυροσινης bruton
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
NO20026255D0 (no) Polymere micelle sammensetninger
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
TW200616640A (en) Novel pharmaceutical formulations of active principles
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
CY1115082T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων
CY1111541T1 (el) Αγωνιστες β-2 αδρενοϋποδοχεα για την αγωγη παθησεων συνδετικου ιστου του δερματος
CY1109120T1 (el) Φαρμακευτικη συνθεση βινφλουνινης που προοριζεται για παρεντερικη χορηγηση, μεθοδος παρασκευης και χρησης
GT200500191A (es) Derivados de pirido - pirimidina, su preparacion, su aplicacion en terapeutica
WO2008030818A3 (en) Novel liposome compositions
CY1116840T1 (el) Χρηση 24-norudca
PA8624401A1 (es) Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo
WO2009032843A3 (en) Deuterated ethambutols and their use